GlassScriptPhysician profile
Austin C Seward
NPI 1245550912
$9,304.51
in general payments reported to CMS, 2019-2025
4 companies · $3,652 in 2025
The $3,652 reported for 2025 was more than what 95% of Oral and Maxillofacial Surgery providers received nationally (typical 2025 total: $150).
See the full distribution for Oral and Maxillofacial Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $461 · 2021: $724 · 2022: $676 · 2023: $2,383 · 2024: $1,266 · 2025: $3,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Travel and Lodging: $2,761 · Gift: $449 · Entertainment: $54.77 · Education: $31.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,004.56 |
| Travel and Lodging | $2,761.40 |
| Gift | $448.95 |
| Entertainment | $54.77 |
| Education | $31.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Straumann USA LLC | $8,980.60 | 2019-2025 | |
| Nobel Biocare USA | $248.87 | 2019-2021 | |
| Geistlich Pharma, North America, INC. | $54.80 | 2019-2021 | |
| Carestream Dental, LLC | $20.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Seward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.